News about Clinical Trials

Gyala Therapeutics Unveils CD84 CAR-T with Strong Pre-clinical Results in Tough Leukemias

Gyala secures €3 million financing from Invivo Partners, Nara Capital and CDTI Innvierte to launch a Phase I trial in AML patients in H2 2025

Clinical Trials | 17/09/2025 | By Dineshwori

BioAge Labs Initiates Phase 1 Trial of Novel NLRP3 Inhibitor BGE-102 for Obesity Treatment

BioAge Labs, a clinical-stage biotechnology company based in Emeryville, California, has announced the initiation of a Phase 1 clinical study of BGE-102, an orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for the treatment of obesity.

Clinical Trials | 16/09/2025 | By Dineshwori

Akeso Doses First Patient in Global Trial of Cadonilimab for PD-1 Resistant Liver Cancer

COMPASSION-36, the first global Phase III trial of Cadonilimab, is underway in China, the US, and Europe. It marks a key step in Akeso's effort to advance cancer immunotherapy beyond single-target treatments.

Clinical Trials | 15/09/2025 | By Dineshwori

Phrontline Biopharma Announces First Patient Dosed in Phase-I Clinical Trial of TJ101

The Phase 1 study of TJ101 will assess its safety, tolerability, pharmacokinetics, and early anti-tumor activity in various solid tumors, using a dose escalation and expansion cohort design.

Clinical Trials | 15/09/2025 | By Dineshwori

NMPA Clears Zhimeng Biopharma's Drug for Phase-II Epilepsy Trial

Zhimeng Biopharma’s drug for Phase II epilepsy trial will be evaluated in a randomized, double-blind, placebo-controlled multinational study to test its efficacy, safety, and tolerability as an adjunct therapy in adults with focal epilepsy.

Clinical Trials | 13/09/2025 | By Dineshwori

Modular Medical Completes MODD1 Clinical Study, Advances Toward Next-Gen Pivot Pump Launch

US-based insulin delivery technology company Modular Medical has announced the successful completion of a clinical study with its MODD1 pump.

Clinical Trials | 12/09/2025 | By Dineshwori |  112

Sanofi Drug Earns Fast Track Status for Wet AMD in US

Sanofi is evaluating SAR402663 in a Phase 1/2 trial (NCT06660667) for neovascular AMD. The gene therapy targets abnormal blood vessel growth, reduces retinal damage, and aims to eliminate the need for frequent intravitreal injections.

Clinical Trials | 11/09/2025 | By Dineshwori

Lilly Drug Jaypirca Delivers Positive Results in CLL Patients

Lilly’s Jaypirca showed a strong Progression-Free Survival (PFS) benefit in front-line CLL, with data from BRUIN studies set to support global label expansion filings.

Clinical Trials | 10/09/2025 | By Dineshwori

Amgen and Kyowa Kirin Report Phase-III Results for Rocatinlimab in Atopic Dermatitis

Amgen and Kyowa Kirin report top-line results from ongoing ASCEND study evaluating Rocatinlimab’s long-term safety and efficacy in adults with moderate to severe Atopic Dermatitis following prior ROCKET trials.

Clinical Trials | 09/09/2025 | By Dineshwori

Mankind Pharma Gets CDSCO Nod to Begin Phase 1 Trials of Novel Autoimmune Drug Candidate MKP11093

Mankind Pharma Ltd., India’s 4th largest pharmaceutical company, today announced that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to initiate a Phase 1 clinical trial of MKP11093, a novel, orally administered Janus kinase-1 (JAK-1) inhibitor.

Clinical Trials | 08/09/2025 | By Darshana